| All patients (N=39) | |
|---|---|
|
Best overall response, n (%)
Complete response (CR) Partial response (PR) Stable disease Progressive disease (PD) Not evaluable Delayed PR* | 2 (5.1) 9 (23.1) 3 (7.7) 20 (51.3) 5 (12.8) 1 (2.6) |
|
Confirmed ORR (CR + PR), n (%)
95% CI | 11 (28.2) 15.0-44.9 |
| Total clinical response rate (ORR + delayed PR), n (%) | 12 (30.8) |
|
Confirmed ORR in subgroups, n/n (%)
Squamous cell carcinoma Adenocarcinoma Prior bevacizumab No prior bevcizumab | 6/24 (25.0) 5/12 (41.7) 6/25 (24.0) 5/14 (35.7) |
|
Duration of response (confirmed ORR), median (range), months
Ongoing response, n/n (%) Duration of ongoing response, months (range) | 11.7 (1.4-41.2) 5/11 (45.5) 1.4-41.2 |
|
Median overall survival, months
95% CI | 13.4 5.5-not reached |
| 24-month overall survival rate,% | 33.2 |
*Patient had a delayed PR after initial disease progression and did not meet response criteria by RECIST 1.1. Duration of response was 23.7 months.